<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62076">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909336</url>
  </required_header>
  <id_info>
    <org_study_id>SIvsSHnh</org_study_id>
    <nct_id>NCT01909336</nct_id>
  </id_info>
  <brief_title>Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia</brief_title>
  <official_title>Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Tecnologico y de Estudios Superiores de Monterey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tecnológico de Monterrey</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Regional Materno Infantil de Alta Especialidad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Tecnologico y de Estudios Superiores de Monterey</source>
  <oversight_info>
    <authority>Mexico: Ethics Committee</authority>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if isotonic solutions reduce the risk of hospital
      acquired hyponatremia compared with hypotonic solutions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, Randomized, Controlled clinical trial.

      The purpose of this study is to determine if isotonic solutions reduce the risk of hospital
      acquired hyponatremia compared with hypotonic solutions

      This study will include 150 patients in 2 groups according to these type of pathology: group
      1: medical conditions which includes respiratory problems (pneumonia, bronchiolitis, acute
      asthma attack) and acute gastrointestinal problems (bacterial or viral gastroenteritis) and
      group 2: surgical conditions (pre, peri or postoperative patients will be included). Each
      group will be randomized to receive 3 types of interventions: 0.3% Saline (hypotonic
      solution), 0.45% Saline (hypotonic solution) or 0.9% Saline (isotonic solution).  In
      non-dehydrated patients the daily total volume of liquid infused will be determined by the
      volumetric Holliday- Segar* formula and the daily total volume will be calculated by adding
      the maintenance requirements (using the Holliday Segar formula) to the fluid deficit
      (according to percent of estimated weight**) in dehydrated patients.

      The glucose concentrations in the first group will be 3.3%, and in group 2 and 3 will be 5%.
      The potassium concentration will be 20mEq/L in all groups. Blood samples will be collected
      before, 8 hours and 24 hours after the start of intravenous fluid, for the analysis of
      sodium, potassium, glucose, urea and creatinine. The adverse clinical outcomes at 8 and 24
      hours of the start of intravenous fluid will also be recorded. The sodium plasma level, the
      incidence of hyponatremia and the adverse clinical outcomes will be compared.

      *0-10 kilogram (kg): 100ml/kg per day; 10-20 kg: 1000 ml + 50 ml/kg/day over 10 kg; &gt;20 kg:
      1500 ml + 20ml/ kg over 20kg

      ** In patients under 10 kg correspond to a loss of 5% (50 mL/kg) in mild dehydration and 10%
      in moderate dehydration. In 10 kg or more: 3% (30 mL/kg) in mild dehydration and 6% (60
      mL/kg) in moderate dehydration.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hospital acquired hyponatremia</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum sodium less than 135 mEq/L at 8 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital acquired hyponatremia</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum sodium less than 135 mEq/L at 24 hours in a patient with normal serum sodium (135 mEq/L to 145mEq/L) at the beginning of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in serum sodium</measure>
    <time_frame>baseline to 8 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>rate of change in serum sodium from baseline to 8 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum sodium</measure>
    <time_frame>Baseline to 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change in serum sodium from baseline to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions attributed to Acute Plasma Sodium Changes</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adjudicated Morbidity Attributed to Acute Plasma Sodium Changes assessed at 24 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 0.45% Saline in 5% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2: 0.45% Saline in 5% dextrose (intravenous)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 0.9% Saline in 5% dextrose (intravenous)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3: 0.9% Saline in 5% dextrose (intravenous)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% Saline in 3.3% dextrose</intervention_name>
    <description>Hypotonic Solutions: 0.3% Saline in 3.3% dextrose</description>
    <arm_group_label>Group 1: 0.3% Saline in 3.3% dextrose (intravenous)</arm_group_label>
    <other_name>Hypotonic Solutions: 0.3% Saline + 3.3% dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.45% Saline in 5% dextrose</intervention_name>
    <description>Hypotonic Solutions: 0.45% Saline in 5% dextrose</description>
    <arm_group_label>Group 2: 0.45% Saline in 5% dextrose (intravenous)</arm_group_label>
    <other_name>Hypotonic Solutions: 0.45% Saline in 5% dextrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline in 5% dextrose</intervention_name>
    <description>Isotonic Solutions 0.9% Saline in 5% dextrose</description>
    <arm_group_label>Group 3: 0.9% Saline in 5% dextrose (intravenous)</arm_group_label>
    <other_name>Isotonic Solutions 0.9% Saline in 5% dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between 3 months to 15 years.

          -  Need for intravenous fluids for 8 hours or more.

          -  Normal serum sodium at the beginning of the study of the study (135-145 mEQ/L).

          -  Acute respiratory problems (acute asthma attack, bronchiolitis or pneumonia).

          -  Acute gastrointestinal disorders (viral o bacterial gastroenteritis).

          -  Elective surgical procedures.

          -  Pre, peri o post operative patients (acute appendicitis, intussusception, intestinal
             perforation, ileus).

        Exclusion Criteria:

          -  Severe hyponatremia (serum sodium &lt; 125 mEq/L).

          -  Severe hypernatremia (serum sodium &gt;155 mEq/L).

          -  Need for intravenous fluids for less than 8 hours according with their treating
             physician.

          -  Severe dehydration or Shock.

          -  Preexisting chronic diseases (renal diseases, heart diseases or endocrine disorders).

          -  Neurologic diseases.

          -  Head trauma.

          -  Cerebral edema or Intracranial hypertension.

          -  Diabetic ketoacidosis.

          -  Use of diuretics one week or less before the study.

          -  Need for admission to the pediatric critical intensive care unit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Montserrat Flores Robles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tecnológico de Monterrey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Alberto Cuello García, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Medicina Basada en Evidencias, Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey.</affiliation>
  </overall_official>
  <reference>
    <citation>Moritz ML, Ayus JC. Hospital-acquired hyponatremia--why are hypotonic parenteral fluids still being used? Nat Clin Pract Nephrol. 2007 Jul;3(7):374-82. Review.</citation>
    <PMID>17592470</PMID>
  </reference>
  <reference>
    <citation>Choong K, Kho ME, Menon K, Bohn D. Hypotonic versus isotonic saline in hospitalised children: a systematic review. Arch Dis Child. 2006 Oct;91(10):828-35. Epub 2006 Jun 5. Review.</citation>
    <PMID>16754657</PMID>
  </reference>
  <reference>
    <citation>Montañana PA, Modesto i Alapont V, Ocón AP, López PO, López Prats JL, Toledo Parreño JD. The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics: a randomized, controlled open study. Pediatr Crit Care Med. 2008 Nov;9(6):589-97. doi: 10.1097/PCC.0b013e31818d3192.</citation>
    <PMID>18838929</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 23, 2013</lastchanged_date>
  <firstreceived_date>July 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Tecnologico y de Estudios Superiores de Monterey</investigator_affiliation>
    <investigator_full_name>Claudia Montserrat Flores Robles, MD</investigator_full_name>
    <investigator_title>Claudia Montserrat Flores Robles</investigator_title>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
